Atomo’s innovative rapid diagnostic test (RDT) platforms simplify procedures, mitigate common user errors, and enhance test performance. Their unmatched usability has won the respect of frontline healthcare providers worldwide, and has made Atomo the OEM partner of choice for diagnostic companies wanting to enhance their RDT product offerings.
Unmatched Usability
User-centred design for professional use & self-test applications.
Proven Performance
Award-winning device platforms that are proven to mitigate user errors.
Efficient Development
Validated processes to accelerate custom device development.
Award-winning AtomoRapid™ RDT platforms remove the need for multiple test components by integrating features into a single device. With assorted functionality, Atomo platforms greatly simplify test procedures.
With a built-in safety lancet, unique blood collection feature, single action blood and buffer delivery system, and interlocked user steps, the AtomoRapid™ Elion self-test platform provides unprecedented usability and performance.
Devices are customisable to suit your requirements and modified to match the specifics of your test strip. From manufacturing process validation to post launch marketing, benefit from Atomo’s dedicated support every step of the way.
HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, July 8, 2019 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device manufacturer At...
09 July, 2019
Seoul, Korea and Sydney, Australia – 29 April 2019 | Access Bio Inc. and Atomo Diagnostics today announced that they have developed a best-in-class ra...
29 April, 2019Following Prequalification approval by the World Health Organization (WHO PQ) for the Mylan HIV Self Test, our partner Mylan is at @IAS_conference in #MexicoCity discussing the latest advances in #HIV testing and access to treatment #IAS2019
#MexicoCity is the stage for the 10th @IAS_conference on HIV Science. We’re excited to be a part of this important event to help advance access to treatment for people living with #HIV.
